Energy, Cognition & Mood
Best Peptides for Focus & Brain Fog: Clinical Evidence (2026)
A clinical, evidence-graded look at the peptides marketed for focus and "brain fog" — Semax, Selank, Cerebrolysin and the N-Acetyl modified analogs — separating the small human attention signal from preclinical mechanism and pure marketing.
SemaxSelankCerebrolysinnootropic peptidesevidence-graded
The quick verdict
An honest, evidence-graded ranking of the peptides marketed for focus and "brain fog" — and why no peptide is a proven fix for a well adult's cognition.
- Best overall
- Semax — The most directly condition-matched peptide — small human studies measured attention and short-term memory — though an independent review judged the evidence insufficient to recommend (Grade B for attention, C for general use).
- Best value
- Semax — The best-evidenced choice for the cost; the pricier N-Acetyl analogs marketed as upgrades have no human or animal data to justify a premium.
- Best for Fog that is mostly anxiety- and stress-driven
- Selank — Its human signal pairs anxiolysis with the absence of sedation and cognitive dulling, so attention is preserved under stress rather than blunted.
How we evaluated
We ranked each peptide strictly by the strength of human evidence for focus or brain fog as a measured endpoint in generally-well people — not fame, mechanism elegance, or evidence for other conditions such as stroke or dementia. Human trials outrank animal data, which outrank in-vitro and mechanism-only reasoning; anecdote and vendor copy do not count. Evidence grades follow PeptideVox's A-to-D ramp (A = human RCT/meta; B = lower-tier human; C = preclinical only; D = anecdotal/marketing), and where a peptide's grade differs by indication we grade it for focus/fog specifically.
- Human focus/fog evidence. Whether any published human study used an attention, memory or cognitive endpoint in a well or fatigued population — not an injured or demented brain.
- Evidence quality. Trial size, blinding, controls, region/language diversity, and whether effect sizes were actually reported.
- Mechanistic coherence. Whether a plausible mechanism (BDNF/TrkB, monoamine potentiation, enkephalin/GABA modulation) supports the claim, ideally with a human correlate.
- Safety & fit. Tolerability for a focus indication specifically — route, stimulation vs sedation, serious-adverse-event signals, and uncharacterized long-term data.
- Regulatory honesty. FDA approval/compounding status and WADA exposure, stated plainly rather than glossed over.
Rating scale: 1-5 stars reflecting human-evidence strength for focus/brain fog specifically: 5 = robust human RCT data in well adults; 1 = mechanism or marketing only. Star ratings track the per-item, condition-specific evidence grade.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Semax | B | 3.0 | Those seeking the single best condition-matched peptide for everyday focus, with eyes open to the thin evidence | Research chemical / not FDA-approved; not a sourcing recommendation |
| 2 | Selank | B | 2.5 | People whose fog is clearly anxiety- and stress-driven and who want calm without cognitive dulling | Research chemical / not FDA-approved; not a sourcing recommendation |
| 3 | Cerebrolysin | A | 2.0 | Understanding the ceiling of peptide evidence — a real drug for injured brains, not a focus aid for healthy ones | No US NDA; legal here only as a non-human research reagent; not a sourcing recommendation |
| 4 | N-Acetyl Semax Amidate | D | 1.5 | Illustrating how marketing outruns evidence — not for anyone seeking proof | Research chemical / not FDA-approved; not a sourcing recommendation |
| 5 | N-Acetyl Selank Amidate | D | 1.5 | The same cautionary lesson as NA-Semax — evidence, not marketing, should drive decisions | Research chemical / not FDA-approved; not a sourcing recommendation |
Semax
The best condition-matched human attention signal
Semax is a Russian-developed synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of ACTH(4-10) engineered to keep the fragment's neurotropic effects while shedding hormonal activity. It ranks first here because it is the only peptide whose human studies actually measured attention and short-term memory. The classic Kaplan/Ashmarin work reported that intranasal Semax improved attention and short-term memory in volunteers across a fatiguing workday, with the largest effect in fatigued subjects and nootropic-like EEG changes. Its strongest clinical data are in acute ischemic stroke: a 110-patient rehabilitation trial using 6,000 micrograms per day in two ten-day courses raised plasma BDNF and accelerated recovery, and a Russian-literature meta-analysis of eight studies reported neurological benefit. The animal mechanism — BDNF/TrkB upregulation plus dopamine and serotonin potentiation — is more consistent than the human cognition data. The critical caveat is that the independent Alzheimer's Drug Discovery Foundation review judges the cognition-specific evidence limited, methodologically weak, and insufficient to recommend Semax for enhancement, with no Phase 2 or 3 RCT for focus in healthy adults. That is why it earns B for the attention signal and only C for general nootropic use.
Strengths
- Only peptide here with human data that actually measured attention and short-term memory
- Effect largest in fatigued subjects — the population most likely to report fog
- Coherent animal mechanism via BDNF/TrkB and stimulated dopamine/serotonin tone
- Genuine human clinical pedigree (acute ischemic stroke recovery, raised plasma BDNF)
Weaknesses
- Human cognition data are small, mostly Russian, often non-blinded; ADDF judged them insufficient to recommend
- No Phase 2/3 RCT for focus in healthy adults; general nootropic use grades only C
- Mildly stimulating — can disturb sleep if dosed late; theoretical caution with stimulants and in diabetes
- Best for
- Those seeking the single best condition-matched peptide for everyday focus, with eyes open to the thin evidence
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Selank
Best matched to anxiety-driven fog
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), an analog of the immunopeptide tuftsin developed at the same Russian institute as Semax. Its relevance to brain fog is indirect but real: much everyday fog is anxiety- and stress-driven, and Selank's signature is anxiolysis without the sedation and attention-dulling that benzodiazepines cause. The pivotal human study is a comparative trial in 62 patients with GAD or neurasthenia, in which Selank matched the benzodiazepine medazepam for anxiolytic efficacy but additionally showed antiasthenic and mild psychostimulant effects with no sedation or cognitive impairment, and a human enkephalin biomarker shifted in support of the proposed mechanism. A randomized, placebo-controlled within-subjects fMRI study in 52 healthy adults found Selank altered right-amygdala and temporal-cortex connectivity — a plausible human neural correlate — though it did not test cognitive performance. The honest caveat is that standalone focus or memory enhancement in healthy people is not supported by adequate human RCTs and is best graded C to D; there is no large independent Western RCT and no meta-analysis. So Selank is B for short-term anxiolysis, the route by which it may help anxiety-driven fog, but weak for making a normal brain sharper. Its advantages over benzodiazepines — no reported dependence or withdrawal — make it the better-fitting choice when fog rides on anxiety.
Strengths
- Directly targets anxiety-driven fog with non-sedating anxiolysis (human GAD trial, Grade B)
- Attention and working memory preserved under anxiety load relative to benzodiazepines
- No reported dependence or withdrawal — a genuine advantage over benzodiazepines
- Human fMRI amygdala-connectivity correlate supports a real central effect
Weaknesses
- Standalone focus/memory enhancement in well people is not supported by adequate RCTs (C-D)
- No large independent placebo-controlled Western RCT and no meta-analysis
- Long-term and rare-event safety uncharacterized; immunogenicity a theoretical concern given its immune-peptide lineage
- Best for
- People whose fog is clearly anxiety- and stress-driven and who want calm without cognitive dulling
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Source: Zozulia et al., Zh Nevrol Psikhiatr 2008 (PMID 18454096)
Cerebrolysin
Grade A — but for injured brains, not healthy focus
Cerebrolysin is the paradox of this list. It is not a single molecule but a porcine-brain-derived peptide and free-amino-acid mixture (roughly 25% low-molecular-weight peptides, 75% amino acids; code FPF-1070), given parenterally only by slow IV infusion or intramuscular injection. It is the only peptide here with a large, genuine human-RCT base — dozens of RCTs and several meta-analyses — but that base is exclusively in damaged brains. The vascular-dementia data are the most internally consistent: a 2013 Cochrane review of six RCTs found cognitive benefit and global response, and a meta-analysis in mild-to-moderate Alzheimer's found a four-week cognitive benefit that faded by six months. Post-stroke motor recovery and TBI series reported benefit on composite endpoints, justifying Grade A for those indications. But three caveats gut its case for healthy focus. First, none of this tested healthy focus or brain fog — every positive trial was in an injured or demented brain, always as an adjunct to standard care — so for healthy enhancement the grade is D. Second, the efficacy direction is sponsor-correlated: the manufacturer-independent 2023 Cochrane stroke review of seven RCTs found no benefit on death or dependence and moderate-certainty evidence of a possible increase in non-fatal serious adverse events, on the basis of which European stroke guidance advises against its use. Third, it is parenteral and porcine-derived, carrying an anaphylaxis risk, and is not a self-administered nootropic.
Strengths
- The only peptide here with a large, genuine human-RCT base (stroke, TBI, vascular dementia, Alzheimer's)
- Consistent vascular-dementia cognitive benefit in a 2013 Cochrane review of six RCTs
- Long clinical track record as an adjunct in injured/diseased brains (Grade A for those indications)
Weaknesses
- Grade D for healthy focus/brain fog — never tested in a well brain
- Independent 2023 Cochrane review found no stroke benefit plus a possible serious-adverse-event signal (RR 2.39)
- Parenteral only (IV/IM), porcine-derived with anaphylaxis risk; seizure contraindication — not a casual nootropic
- Best for
- Understanding the ceiling of peptide evidence — a real drug for injured brains, not a focus aid for healthy ones
- Pricing
- No US NDA; legal here only as a non-human research reagent; not a sourcing recommendation
Source: Ziganshina et al., Cochrane CD007026 2023 (PMC10565895)
N-Acetyl Semax Amidate
The most-marketed focus peptide with zero trials
N-Acetyl Semax Amidate (NA-Semax) is a terminally-stabilized designer analog of Semax — an N-terminal acetyl cap plus a C-terminal amide (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, PubChem CID 172638603) intended to slow exopeptidase degradation and, in theory, extend half-life and potency. It is among the forms most heavily marketed specifically for focus and brain fog, which makes its evidence gap the central honesty point of this ranking. There are no published clinical trials, no registered ClinicalTrials.gov studies, and no peer-reviewed animal efficacy studies for this modified analog. Every human claim is anecdotal or extrapolated from the parent peptide. The widely repeated figures — three-to-four-times more potent, roughly thirty minutes longer half-life, a 200-to-300-minute half-life — originate from vendor copy and structure-activity reasoning, not measured data for this specific molecule. Acetylation plus amidation is a chemically sound stabilization strategy in principle, but terminal caps could preserve, enhance, or subtly alter target engagement, and that has never been tested. Whatever modest evidence exists belongs to unmodified Semax (B to C), and it does not transfer automatically to a chemically altered analog. It ranks above its Selank counterpart only because its parent scaffold has the better condition-matched human data; on its own merits, for focus specifically, it is Grade D, unproven, and paying a premium for it is the opposite of evidence-based.
Strengths
- Built on the Semax scaffold, the one peptide here with real human attention data
- Acetylation plus amidation is a chemically rational stabilization strategy in principle
- If the modification preserves activity, it could in theory extend duration
Weaknesses
- Zero clinical trials, zero registered studies, zero peer-reviewed animal efficacy work
- Potency and half-life multipliers trace only to vendor copy and structure-activity guessing
- No safety data of its own; profile borrowed from the parent, plus research-chemical purity risk
- Best for
- Illustrating how marketing outruns evidence — not for anyone seeking proof
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
N-Acetyl Selank Amidate
A stabilized Selank analog with no data at all
N-Acetyl Selank Amidate (NA-Selank) is the terminally-stabilized designer analog of Selank (Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2), carrying the same N-terminal acetyl cap and C-terminal amide intended to slow enzymatic breakdown and extend duration. Like its Semax counterpart it is heavily marketed for focus and calm-focus, and like its counterpart it has no evidence of its own: no published clinical trials, no registered studies, and no peer-reviewed animal efficacy work exist for this modified molecule. Every benefit claimed for it is extrapolated from parent Selank purely by structural analogy. The specific vendor claims — longer half-life, greater potency, better blood-brain-barrier penetration — appear only in vendor and SEO copy with no primary citation, and no measured pharmacokinetic study has ever characterized it. Terminal caps are a rational stabilization strategy in principle, but whether they preserve, enhance, or subtly alter Selank's activity is untested. It ranks last here because its parent, while genuinely useful for anxiety, is only indirectly relevant to focus, and the modification adds cost and uncertainty without adding a single data point. On its own merits, for focus and brain fog specifically, it is Grade D, unproven. Do not assume the parent's human anxiety results transfer to this altered analog, and do not let the longer name imply a stronger product.
Strengths
- Built on the Selank scaffold, which has genuine human anxiety data
- Acetylation plus amidation is a chemically rational stabilization strategy in principle
- If the modification preserves activity, it could in theory extend duration
Weaknesses
- Zero dedicated human or animal studies and no measured pharmacokinetics
- Half-life, potency and BBB-penetration claims trace only to vendor copy with no primary source
- Toxicology, adverse-event and interaction data are entirely absent; research-chemical purity risk
- Best for
- The same cautionary lesson as NA-Semax — evidence, not marketing, should drive decisions
- Pricing
- Research chemical / not FDA-approved; not a sourcing recommendation
Source: Peptides.org — N-Acetyl Selank Amidate review (2026)
Feature comparison
| Feature | Semax | Selank | Cerebrolysin | N-Acetyl Semax Amidate | N-Acetyl Selank Amidate |
|---|---|---|---|---|---|
| Human focus/attention data | ✓ | Under-stress only | Injured brains only | — | — |
| Evidence grade (focus/fog) | B-C | B (anxiety) / C-D (focus) | A (injury) / D (focus) | D | D |
| Focus endpoint studied in well adults | ✓ | — | — | — | — |
| Feature | Semax | Selank | Cerebrolysin | N-Acetyl Semax Amidate | N-Acetyl Selank Amidate |
|---|---|---|---|---|---|
| Route | Intranasal | Intranasal | Parenteral (IV/IM) | Intranasal | Intranasal |
| Feature | Semax | Selank | Cerebrolysin | N-Acetyl Semax Amidate | N-Acetyl Selank Amidate |
|---|---|---|---|---|---|
| FDA compounding review 2026 | Yes (Jul 24 PCAC) | Off Category 2, not on agenda | No US pathway | Not on any FDA list | Not on any FDA list |
| WADA exposure (S0) | Prohibited (catch-all) | Prohibited (catch-all) | Prohibited (catch-all) | Prohibited (catch-all) | Prohibited (catch-all) |
Frequently asked
What is the single best peptide for brain fog and focus?
There is no clear winner with strong human evidence. For everyday focus, Semax has the most directly relevant data — small, mostly Russian human studies that actually measured attention and short-term memory, with the largest effect in fatigued subjects. But the independent Alzheimer's Drug Discovery Foundation review judges that evidence limited, methodologically weak, and insufficient to recommend Semax for cognitive enhancement. If your fog is anxiety-driven, Selank is the better-matched mechanism, offering non-sedating anxiolysis that preserves attention under stress, though again without large Western RCTs. Cerebrolysin has genuine Grade-A data, but only for injured and diseased brains, not healthy focus. So the honest answer is that a coherent mechanism exists, but no peptide is a proven treatment for focus or brain fog in well adults.
Are the N-Acetyl versions of Semax and Selank stronger?
Unknown, and that is the honest answer. There are no published clinical trials, no registered ClinicalTrials.gov studies, and no peer-reviewed animal efficacy studies for either N-Acetyl Semax Amidate or N-Acetyl Selank Amidate. Every human claim is anecdotal or extrapolated from the parent peptide. The widely repeated figures of three-to-four-times potency and a 200-to-300-minute half-life originate from vendor copy and structure-activity reasoning, not measured data for these specific molecules. Whatever modest evidence exists belongs to the unmodified parents — Semax at B to C, Selank at B — and it does not transfer automatically to a chemically altered analog. These are graded D uniformly. Paying more for an unstudied analog of a barely-studied peptide is the opposite of evidence-based decision-making.
Is Cerebrolysin a good nootropic for a healthy person with brain fog?
No. Cerebrolysin is the one peptide here with a large, genuine human-RCT base, but that base is exclusively in damaged brains — acute stroke, traumatic brain injury, vascular dementia and Alzheimer's — always as an adjunct to standard care. None of it tested healthy focus or brain fog, so for that use it is Grade D. It is also parenteral only, given by IV infusion or intramuscular injection rather than a casual nasal spray, and it is porcine-brain-derived, carrying an anaphylaxis risk. Critically, the manufacturer-independent 2023 Cochrane stroke review found no benefit on death or dependence and moderate-certainty evidence of a possible increase in non-fatal serious adverse events, on the basis of which European stroke guidance advises against its use.
Do any of these peptides help long-COVID brain fog?
The rationale is mechanistically plausible. Long-COVID brain fog is thought to involve neuroinflammation, mitochondrial dysfunction and neurotransmitter imbalance, and Semax and Selank act on BDNF, monoamine and enkephalin pathways that could in theory support a fog-prone brain. Because of this, both are widely discussed online for post-viral cognitive impairment. However, robust Phase 2 and Phase 3 randomized controlled trial data in long-COVID cognitive impairment are lacking; the current support is preliminary and mechanistic rather than proven. From a functional, root-cause standpoint these peptides might support recovery but do not fix the upstream driver. Anyone with persistent post-viral fog should be evaluated by a clinician for treatable contributors such as sleep disruption, dysautonomia, thyroid dysfunction and mood before turning to unapproved peptides.
Are these peptides legal to buy and use in the U.S. in 2026?
None is FDA-approved for any cognitive use. Semax and Selank were both removed from FDA 503A Category 2 in 2026, and Semax is scheduled for a Pharmacy Compounding Advisory Committee review on July 24, 2026 under docket FDA-2025-N-6895 — a pending, non-binding step, not an approval. Removal from Category 2 is not authorization to compound, and Selank is not even on the July 2026 agenda. The N-Acetyl modified analogs are named in no FDA list and have no compounding pathway, and Cerebrolysin has never had a U.S. NDA. All are sold only as research chemicals labeled not for human consumption, of unverified purity and with no pharmacovigilance. For tested athletes, treat all of them as captured by the WADA S0 non-approved-substances catch-all and prohibited at all times.
Does Semax actually treat ADHD or attention disorders?
There is no trial evidence that it does. The frequently cited link between Semax and ADHD traces to a single 2007 Medical Hypotheses paper, which is a mechanistic hypothesis proposing Semax as a potential attention agent, not a clinical trial and not efficacy data. No regulator recommends Semax for ADHD or any attention disorder, and no controlled study has tested it against a validated attention-disorder endpoint. The human attention signal that does exist comes from small studies of healthy or fatigued volunteers measuring short-term memory and vigilance, not diagnosed ADHD. Treating a hypothesis paper as if it were a positive trial is exactly the kind of evidence inflation this ranking is designed to flag. Attention disorders should be assessed and managed by a qualified clinician.